WEBINAR: Microbiome Analysis at Strain-Level: Study Design for
Pre-Clinical and Clinical Drug Development
Next-Generation Sequencing has revolutionized microbiological sciences by revealing that virtually all environments, including the human body, are teeming with diverse microbial communities.
It has become evident that the human microbiota contributes biological functions that are essential to our well-being. Conversely, disrupting the healthy homeostasis of host and microbiome can lead to dysbiosis and has been implicated in many diseases and pathologies. As a consequence, research into the human microbiome is beginning to transform the healthcare landscape by providing novel diagnostic and therapeutic approaches.
In this webinar, Dr. Materna will present an overview of the different phases involved in the development of microbiome-based therapies, including target discovery, pre-clinical and clinical research, production and quality assurance. He will introduce common challenges specific to microbiome studies and will discuss solutions along all phases of drug development using real-world examples.
Arne Materna, Ph.D.
A microbiologist and molecular biologist by training, Arne Materna received his doctoral degree from the University of Konstanz, Germany, and his postdoctoral training at the Massachusetts Institute of Technology. Dr. Materna later joined Pacific Biosciences as Systems Architect responsible for the system level modeling of a new Next-generation Sequencing device.
In 2012 Dr. Materna joined CLC bio, acquired by QIAGEN in 2013. As Director for Genome Analysis Dr. Materna was responsible for several segments in QIAGEN’s portfolio of bioinformatics solutions. Today, Dr. Materna is part of CosmosID’s leadership team and directs the product management and marketing department.